Government regulators said Thursday recent studies highlight the potential fatal danger of anemia drugs sold by Johnson & Johnson and Amgen when used in certain cancer patients. The Food and Drug Administration said it is considering taking “additional action” to increase the safe use of Amgen’s Epogen and Aranesp and Johnson & Johnson’s Procrit, after reviewing data first disclosed by the companies in early December.
